secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROKIDNEY CORP. (PROK)
CIK:        0001850270
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0000950170-24-057443
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProKidney reports Q1 net loss $35.3M, cash $329M; Phase 2 data to be presented May 25
--------------------------------------------------------------------------------

- RMCL-002 Phase 2 final results to be presented at ERA Congress on May 25, 2024; investor call on May 28.
- PROACT 1 protocol amendment submitted to FDA focusing on severe CKD (eGFR 20-35); enrollment to resume mid-2024.
- Appointed Ulrich Ernst as EVP Technical Operations and Lucio Tozzi as SVP Global Clinical Operations.
- Cash and equivalents $329M as of March 31, 2024, supporting operations into Q4 2025.
- Net loss before noncontrolling interest $35.3M for Q1 2024 vs $36.9M same period 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850270/000095017024057443/0000950170-24-057443-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850270/000095017024057443/prok-20240510.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-057443

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer